ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Clinical trials for ERYTHROPOIETIC PROTOPORPHYRIA (EPP) explained in plain language.
Never miss a new study
Get alerted when new ERYTHROPOIETIC PROTOPORPHYRIA (EPP) trials appear
Sign up with your email to follow new studies for ERYTHROPOIETIC PROTOPORPHYRIA (EPP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to let sunlight-sensitive patients enjoy the sun longer
Symptom relief CompletedThis study tested a drug called MT-7117 in 165 adults and adolescents (ages 12-75) with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), conditions that cause severe pain from sunlight exposure. The goal was to see if the drug could delay the first symptoms o…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New pill could let EPP patients enjoy the sun without pain
Symptom relief CompletedThis phase 2 trial tested a drug called MT-7117 in 102 adults with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain from sunlight. Participants took either a low dose, high dose, or placebo daily for 16 weeks. The goal was to see if the drug could inc…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Phase: PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC